source
- Clinical Scenario Presentation and Treatment Approach for Progressive DiseaseExperts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.onclive · 2mo ago↗ source
- Dr Pant on the Mechanism of Action of Daraxonrasib in PDACShubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.onclive · 2mo ago↗ source
- Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.onclive · 2mo ago↗ source